US 12,187,800 B2
Anti-B7-H3 antibody
Li Guo, Beijing (CN); Yuan Dou, Beijing (CN); Tiantian Sun, Beijing (CN); Jiaming Li, Beijing (CN); Xiaoxu Qi, Beijing (CN); and Chen Dong, Beijing (CN)
Assigned to SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD., Jiangsu (CN); and BEIJING KANOVA BIOPHARMACEUTICALS CO. LTD., Beijing (CN)
Appl. No. 17/295,896
Filed by SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD., Jiangsu (CN); and BEIJING KANOVA BIOPHARMACEUTICAL CO., LTD., Beijing (CN)
PCT Filed Nov. 22, 2018, PCT No. PCT/CN2018/117011
§ 371(c)(1), (2) Date May 21, 2021,
PCT Pub. No. WO2020/103100, PCT Pub. Date May 28, 2020.
Prior Publication US 2022/0119529 A1, Apr. 21, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. An isolated antibody or antigen binding fragment thereof, comprising a heavy chain (HC) variable region sequence and a light chain (LC) variable region sequence, wherein the antibody binds to an extracellular domain of B7-H3 with a binding affinity of about 1.5 nM or better than 1.5 nM as determined by SPR analysis
wherein the HC comprises
(a) a HC CDR1 comprising the amino acid sequence GYNFNNYWMH (SEQ ID NO: 1); and
(b) a HC CDR2 comprising the amino acid sequence MIHPNSGTFNYNERFKR (SEQ ID NO: 2); and
(c) a HC CDR3 comprising the amino acid sequence STALATDY (SEQ ID NO: 3); and wherein
the LC comprises
(a) a LC CDR1 comprising the amino acid sequence SASSSVSYMY (SEQ ID NO: 4); and
(b) a LC CDR2 comprising the amino acid sequence DTSNLAS (SEQ ID NO: 5); and
(c) a LC CDR3 comprising the amino acid sequence QQWSSYPLT (SEQ ID NO: 6);
or wherein the HC comprises
(a) a HC CDR1 comprising the amino acid sequence GYTFTNYWMH (SEQ ID NO: 7); and
(b) a HC CDR2 comprising the amino acid sequence MIHPNSGAFNYNERFKT (SEQ ID NO: 8); and
(c) a HC CDR3 comprising the amino acid sequence STALATGY (SEQ ID NO: 9); and the LC comprises
(a) a LC CDR1 comprising the amino acid sequence SASSSVSYMY (SEQ ID NO: 10); and
(b) a LC CDR2 comprising the amino acid sequence DTSNLAS (SEQ ID NO: 11); and
(c) a LC CDR3 comprising the amino acid sequence QQWSSYPLT (SEQ ID NO: 12).